Allworth Financial’s Sarepta Therapeutics SRPT Stock Holding History

Allworth Financial’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$57.5K	Sell	3,200 -6,067	-65%	-$115K	﹤0.01%	2358
2026 Q1	$202K	Buy	9,267 +1,872	+25%	+$36.2K	﹤0.01%	1400
2025 Q4	$159K	Buy	7,395 +5,592	+310%	+$118K	﹤0.01%	1471
2025 Q3	$34.7K	Buy	1,803 +1,721	+2,099%	+$30.7K	﹤0.01%	2360
2025 Q2	$1.4K	Sell	82 -123	-60%	-$5.25K	﹤0.01%	3853
2025 Q1	$12.7K	Buy	205 +73	+55%	+$7.68K	﹤0.01%	2321
2024 Q4	$15.3K	Buy	132 +50	+61%	+$6.13K	﹤0.01%	2254
2024 Q3	$10.2K	Buy	82 +17	+26%	+$2.35K	﹤0.01%	2243
2024 Q2	$9.46K	Buy	65 +23	+55%	+$2.96K	﹤0.01%	2242
2024 Q1	$5.44K	Sell	42 -48	-53%	-$5.88K	﹤0.01%	2376
2023 Q4	$8.68K	Buy	90 +9	+11%	+$863	﹤0.01%	2039
2023 Q3	$9.82K	Buy	81 +45	+125%	+$5.09K	﹤0.01%	1850
2023 Q2	$4.12K	Sell	36 -8	-18%	-$1.03K	﹤0.01%	2186
2023 Q1	$6.07K	Buy	44 +17	+63%	+$2.21K	﹤0.01%	1967
2022 Q4	$3.5K	Sell	27 -3	-10%	-$348	﹤0.01%	2030
2022 Q3	$3K	Buy	30 +24	+400%	+$2.42K	﹤0.01%	2063
2022 Q2	$0	Sell	6 -165	-96%	-$12.1K	﹤0.01%	2788
2022 Q1	$13K	Buy	+171	New	+$13.1K	﹤0.01%	1415
2021 Q4	–	Sell	-634	Closed	-$59K	–	2108
2021 Q3	$59K	Buy	634 +135	+27%	+$10.4K	﹤0.01%	744
2021 Q2	$39K	Sell	499 -200	-29%	-$15.2K	﹤0.01%	681
2021 Q1	$52K	Hold	699	–	–	﹤0.01%	568
2020 Q4	$119K	Hold	699	–	–	﹤0.01%	349
2020 Q3	$98K	Hold	699	–	–	﹤0.01%	331
2020 Q2	$112K	Hold	699	–	–	﹤0.01%	298
2020 Q1	$68K	Hold	699	–	–	﹤0.01%	360
2019 Q4	$90K	Hold	699	–	–	﹤0.01%	290
2019 Q3	$53K	Hold	699	–	–	﹤0.01%	313
2019 Q2	$106K	Hold	699	–	–	﹤0.01%	229
2019 Q1	$83K	Hold	699	–	–	﹤0.01%	252
2018 Q4	$76K	Hold	699	–	–	﹤0.01%	244
2018 Q3	$113K	Hold	699	–	–	0.01%	207
2018 Q2	$92K	Hold	699	–	–	﹤0.01%	214
2018 Q1	$52K	Hold	699	–	–	﹤0.01%	247
2017 Q4	$39K	Hold	699	–	–	﹤0.01%	275
2017 Q3	$32K	Buy	699 +300	+75%	+$12K	﹤0.01%	291
2017 Q2	$13K	Hold	399	–	–	﹤0.01%	441
2017 Q1	$12K	Hold	399	–	–	﹤0.01%	423
2016 Q4	$11K	Hold	399	–	–	﹤0.01%	393
2016 Q3	$25K	Hold	399	–	–	﹤0.01%	296
2016 Q2	$8K	Hold	399	–	–	﹤0.01%	417
2016 Q1	$8K	Hold	399	–	–	﹤0.01%	402
2015 Q4	$15K	Hold	399	–	–	﹤0.01%	344
2015 Q3	$13K	Hold	399	–	–	﹤0.01%	364
2015 Q2	$12K	Hold	399	–	–	﹤0.01%	366
2015 Q1	$5K	Buy	+399	New	+$5.32K	﹤0.01%	448

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Allworth Financial's SRPT Position: Q2 2026 in Review

Allworth Financial reduced its Sarepta Therapeutics (SRPT) stake by 65% in Q2 2026, selling an estimated $115K and leaving 3,200 shares worth $57.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2358.

Allworth Financial first reported a position in SRPT in Q1 2015 and has held it in 45 quarters since. The position peaked at $202K in Q1 2026. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Allworth Financial held 3,200 shares of Sarepta Therapeutics worth $57.5K as of Q2 2026.
Allworth Financial sold 6,067 Sarepta Therapeutics shares in Q2 2026, an estimated $115K.
Sarepta Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #2358 holding.
Allworth Financial first reported a position in Sarepta Therapeutics in Q1 2015 and has held it in 45 quarters since.
Allworth Financial's Sarepta Therapeutics position peaked at $202K in Q1 2026.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.